SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Bayer Aktiengesellschaft, et al. – ‘3’ for 10/18/16 re: CRISPR Therapeutics AG – ‘EX-24’

On:  Tuesday, 10/18/16, at 7:45pm ET   ·   For:  10/18/16   ·   Accession #:  899243-16-31911   ·   File #:  1-37923

Previous ‘3’:  None   ·   Next:  ‘3’ on 8/3/20 for 8/1/20   ·   Latest:  ‘3’ on 2/15/24 for 2/8/24

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

10/18/16  Bayer Aktiengesellschaft          3                      2:10K  CRISPR Therapeutics AG            Donnelley Fin’l S… 06/FA
          Bayer Global Investments B.V.

Initial Statement of Beneficial Ownership of Securities by an Insider   —   Form 3   —   SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 3           Form 3 Submission -- doc3.xml/2.6                   HTML      3K 
 2: EX-24       EX-24 Document                                      HTML      7K 


‘EX-24’   —   EX-24 Document


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



                                                                      Exhibit 24

                               POWER OF ATTORNEY

                (For Executing Form ID and Forms 3, 4 and 5 and
                             Schedules 13D and 13G)

Know all by these presents that the undersigned hereby constitutes and appoints
each of Dr. Jan Heinemann, Dr. Paul Fort and Dr. Thomas Reuter, signing
individually, the undersigned's true and lawful attorneys-in fact and agents to:

(1) Prepare, execute in the undersigned's name and on the undersigned's behalf,
and submit to the Securities and Exchange Commission a Form ID, including
amendments thereto, and any other documents necessary or appropriate to obtain
codes and passwords enabling the undersigned to make electronic filings with the
Securities and Exchange Commission of reports required by Sections 13 and  16(a)
of the Securities Exchange Act of 1934 or any rule or regulation thereunder;

(2) Prepare, execute in the undersigned's name and on the undersigned's behalf,
and submit to the Securities and Exchange Commission Forms 3, 4 and 5 and
Schedules 13D and 13G  (including amendments thereto and joint filing agreements
in connection therewith) in accordance with Sections 13 and  16(a) of the
Securities Exchange Act of 1934 and the rules thereunder;

(3) Do and perform any and all acts for and on behalf of the undersigned that
may be necessary or desirable to prepare and execute any such Form 3, 4 or 5 and
Schedules 13D and 13G (including amendments thereto and joint filing agreements
in connection therewith) and file such Forms and Schedules with the Securities
and Exchange Commission and any stock exchange, self-regulatory association or
any other authority; and

(4) Take any other action of any type whatsoever in connection with the
foregoing that, in the opinion of such attorney-in-fact, may be of benefit to,
in the best interest of, or legally required of the undersigned, it being
understood that the documents executed by the attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as the attorney-in-fact may approve in the
attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this power of attorney and the rights and powers herein
granted. The undersigned acknowledges that the foregoing attorneys-in-fact, and
their substitutes, in serving in such capacity at the request of the
undersigned, are not assuming  any of the undersigned's responsibilities to
comply with Sections 13 and  16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4 and 5 and Schedules 13D and
13G with respect to the undersigned's holdings of and transactions in securities
issued by CRISPR Therapeutics AG (the "Company"), unless earlier revoked by the
undersigned in a signed writing delivered to the Company and the attorneys-in
fact. This Power of Attorney revokes any other power of attorney that the
undersigned has previously granted with respect to such filings.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of the date written below.

Dated:  October 12, 2016

                                      Bayer Global Investments B.V.

                                      By: /s/ Axel Steiger-Bagel
                                      Name: Dr. Axel Steiger-Bagel
                                      Title: Managing Director

                                      By: /s/ Adri Koersvelt
                                      Name: Adri Koersvelt
                                      Title: Managing Director


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘3’ Filing    Date    Other Filings
Filed on / For Period end:10/18/163,  3/A,  4,  8-A12B,  CERTNAS,  CT ORDER,  EFFECT
10/12/16DFAN14A
 List all Filings 
Top
Filing Submission 0000899243-16-031911   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Mon., May 6, 8:17:38.1pm ET